Domo signs strategic collaboration agreement with AWS for AI solutions
Investing.com -- OmniAb Inc (NASDAQ:OABI) stock tumbled 9.2% in Monday’s premarket trading after the company announced a private placement of shares that will dilute existing shareholders.
The antibody discovery platform company revealed it has entered into a definitive agreement to sell over 21.25 million shares of its common stock at $1.40 per share, with officers and directors participating at a higher price of $1.85 per share. The private placement is expected to generate approximately $30 million in gross proceeds before fees and expenses.
OmniAb indicated the net proceeds will be used for "general corporate purposes," without providing specific details on planned expenditures. The transaction, which includes participation from both new and existing investors, is expected to close around August 26, 2025, subject to customary closing conditions.
Leerink Partners is serving as the sole placement agent for the transaction. The shares being sold have not been registered under the Securities Act of 1933 and cannot be offered or sold in the United States without registration or an applicable exemption. However, OmniAb has agreed to file a registration statement with the SEC to enable the resale of these shares.
The significant share dilution appears to be driving the negative market reaction, as the new shares represent a substantial addition to the company’s outstanding stock count at a price below recent trading levels.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.